Physician profile
James B Sterner
NPI 1336361948
$2,674.83
in general payments reported to CMS, 2019-2025
29 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $127 · 2021: $346 · 2022: $517 · 2023: $760 · 2024: $550 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Consulting Fee: $37.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.92 |
| Consulting Fee | $37.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $535.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $522.06 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $220.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $174.23 | 2020-2025 | Hyqvia, Cuvitru |
| Hospira, INC. | $144.73 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $123.89 | 2021-2025 | Orladeyo |
| Csl Behring | $96.02 | 2019-2023 | Haegarda, Kcentra |
| Regeneron Healthcare Solutions, INC. | $88.51 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $84.26 | 2022-2023 | Adbry |
| Amgen INC. | $81.38 | 2019-2025 | Tezspire |
| Grifols USA, LLC | $75.02 | 2020-2024 | Xembify |
| Genentech USA, INC. | $58.66 | 2020-2024 | Xolair |
| Hikma Pharmaceuticals USA | $50.42 | 2023-2024 | Ryaltris |
| Pharming Healthcare, INC. | $49.15 | 2021-2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $48.26 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.28 | 2022 | |
| Lilly USA, LLC | $44.91 | 2021-2025 | Ebglyss |
| Greer Laboratories, INC. | $38.45 | 2023-2024 | Palforzia, Oralair |
| Adma Biomanufacturing LLC | $37.41 | 2023 | |
| Pfizer INC. | $36.22 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2021 | |
| Kaleo, INC. | $22.65 | 2023 | Auvi-Q |
| Blueprint Medicines Corporation | $21.65 | 2023 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $19.68 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $16.69 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $16.17 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sterner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.